The relationship between body composition and response to neoadjuvant chemotherapy in women with operable breast cancer

Oncologist

Volumn 17, Issue 10, 2012, Pages 1240-1245

  Del Fabbro, Egidio ^a   Parsons, Henrique ^a   Warneke, Carla L ^a   Pulivarthi, Kalyan ^a   Litton, Jennifer K ^a   Dev, Rony ^a   Palla, Shana L ^a   Brewster, Abenaa ^a   Bruera, Eduardo ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Body composition; Breast cancer; Clinical outcome

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BODY MASS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DEATH; FEMALE; HUMAN; INTRAABDOMINAL FAT; MAJOR CLINICAL STUDY; MUSCLE ATROPHY; OBESITY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; TREATMENT RESPONSE;

BODY COMPOSITION; BODY MASS INDEX; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; NEOADJUVANT THERAPY; OBESITY; OVERWEIGHT; SARCOPENIA; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84868143884     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2012-0169     Document Type: Article

References (22)

1. van Kruijsdijk RC, van der Wall E, Visseren FL. Obesity and cancer: The role of dysfunctional adipose tissue. Cancer Epidemiol Biomarkers Prev 2009;18:2569-2578.
2. Chlebowski RT, Aiello E, McTiernan A. Weight loss in breast cancer patient management. J Clin Oncol 2002;20:1128-1143.
3. Baumgartner RN, Koehler KM, Gallagher D et al. Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol 1998;147:755-763.
4. Roubenoff R. Sarcopenia: Effects on body composition and function. J Gerontol A Biol Sci Med Sci 2003; 58:1012-1017.
5. Parsons HA, Baracos VE, Dhillon N et al. Body composition, symptoms, and survival in advanced cancer patients referred to a phase I service. PLoS One 2012; 7:e29330.
6. Prado CM, Baracos VE, McCargar LJ et al. Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res 2009; 15:2920-2926.
7. Prado CM, Lima IS, Baracos VE et al. An exploratory study of body composition as a determinant of epirubicin pharmacokinetics and toxicity. Cancer Chemother Pharmacol 2011;67:93-101.
8. Antoun S, Baracos VE, Birdsell L et al. Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma. Ann Oncol 2010;21:1594-1598.
9. Litton JK, Gonzalez-Angulo AM, Warneke CL et al. Relationship between obesity and pathologic response to neoadjuvant chemotherapy among women with operable breast cancer. J Clin Oncol 2008;26:4072-4077.
10. Guarneri V, Broglio K, Kau SW et al. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol 2006;24:1037-1044.
11. Hennessy BT, Hortobagyi GN, Rouzier R et al. Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy. J Clin Oncol 2005;23: 9304-9311.
12. National Institutes of Health/National Heart, Lung, and Blood Institute: Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. Available at http://www.nhlbi.nih. gov/guidelines/obesity/ob_gdlns.htm, accessed July 25, 2012.
13. Kvist H, Sjöström L, Tylén U. Adipose tissue volume determinations in women by computed tomography: Technical considerations. Int J Obes 1986;10:53-67.
14. Prado CM, Lieffers JR, McCargar LJ et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: A population-based study. Lancet Oncol 2008;9:629-635.
15. Tan BH, Birdsell LA, Martin L et al. Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer. Clin Cancer Res 2009;15: 6973-6979.
16. Morgan DJ, Bray KM. Lean body mass as a predictor of drug dosage. Implications for drug therapy. Clin Pharmacokinet 1994;26:292-307.
17. Santini F, Pinchera A, Marsili A et al. Lean body mass is a major determinant of levothyroxine dosage the treatment of thyroid diseases. J Clin Endocrinol Metab 2005;90:124-127.
18. Dewys WD, Begg C, Lavin PT et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Am J Med 1980;69:491-497.
19. Fearon K, Strasser F, Anker SD et al. Definition and classification of cancer cachexia: An international consensus. Lancet Oncol 2011;12:489-495.
20. Baracos VE, Reiman T, Mourtzakis M et al. Body composition in patients with non-small cell lung cancer: A contemporary view of cancer cachexia with the use computed tomography image analysis. Am J Clin Nutr 2010;91:1133S-1137S.
21. Stephens NA, Gray C, Macdonald AJ et al. Sexual dimorphism modulates the impact of cancer cachexia lower limb muscle mass and function. Clin Nutr 2012; 31:499-505.
22. Palomares MR, Sayre JW, Shekar KC et al. Gender influence on weight-loss pattern and survival of nonsmall cell lung carcinoma patients. Cancer 1996; 78:2119-2126.